Home - SoftOx Solutions

ABOUT US

A pharmaceutical company

SoftOx Solutions AS (SoftOx, listed at Euronext Growth Oslo) is a clinical-stage pharmaceutical company based in Oslo, Norway. We have developed a non-toxic and highly efficient antimicrobial technology designed to address some of the world’s greatest health challenges, including:

Targeting airway infections with endogenous molecule

The SoftOx technology stabilizes an endogenous pan-antimicrobial molecule (HOCl) thereby enhancing one of the immune system’s ways of eradicating pathogens in the airways.

Alleviating antimicrobial resistance (AMR) development

As HOCl’s mode of action is unspecific and metabolic independent, no resistance develops when using SoftOx technology. According to the World Health Organization, AMR is a major threat to global health. New forms of resistance are emerging and can spread with remarkable speed between continents. Therefore, the SoftOx technology is likely highly important to counteract this detrimental development.

VAP and chronic infections

SoftOx Inhalation Solution (SIS) is effective against pathogens causing VAP as well as other airway infections/pneumonia. With inhaled administration of the nebulized SIS, the treatment will be local, tolerable and is expected to be highly effective.

Spread of viruses

Deadly viral outbreaks are expected in the future. There remains an unmet need for effective and well-tolerated virucidal solutions to aid infection prevention and control. SoftOx Inhalation Solution (SIS) has a strong virucidal capacity.

OUR VISION

New ways of eradicating infections

Our vision seemed almost unreachable when SoftOx began work on its formulations 10 years ago. It took plenty of hard work, a strong belief in our research, and a stubbornness to overcome uncertainties, setbacks, and other challenges, and get to where we are today. Thanks to the dedication and commitment of our team, and to the core values we all share, SoftOx is currently in a prime position.

As SoftOx develops into a well-known brand, we will learn to navigate various obstacles. It is therefore important to emphasize that our long-term goals are now within reach, and our ongoing research and development have resulted in greater confidence and optimism than ever before.

Charles Alexandre de Calonne once said: “Nothing is impossible, the impossible just takes a little longer”. This statement corresponds well with our dedication to developing solutions serving human health.

Laboratory beaker in analyst's hand in plastic glove.

WE ARE COLLABORATING WITH

Leading Research Institutions & Organisations

After years of research and product development

In collaboration With leading Nordic research institutes

SoftOx has developed a non-toxic and highly effective antimicrobial technology, which eradicates and prevents biofilm infections and is fully virucidal.

SoftOx is all about Technology

SoftOx Inhalation Solution (SIS) is built on the Company’s proprietary technology platform, developed in collaboration with leading scientists and clinicians from universities in Skåne County and the University of Copenhagen. The technology is based on a combination of naturally occurring compounds with broad antimicrobial activity and a low propensity for resistance development.

Preclinical data demonstrate activity against a wide range of pathogens, including Gram-positive and Gram-negative bacteria (including resistant strains such as MRSA), fungi, and viruses. Clinical experience to date indicates that the inhaled formulation is well tolerated.

Through localized airway delivery via nebulization, SIS is designed to provide targeted antimicrobial activity at the site of infection while minimizing systemic exposure. By addressing biofilm-associated and tolerant pathogens, SIS aims to improve the treatment of chronic and acute respiratory infections where conventional antibiotics may have limited effectiveness.

Developed With Top Ranked Scientists

Aiming to Solve Major Health Challenges